NCT01746771View on ClinicalTrials.gov

A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
HER-2 Positive Advanced Gastric Cancer
Interventions
DRUG

HM781-36B(Poziotinib)

QD\*2weeks/3weeks

DRUG

Paclitaxel

175mg/m2

DRUG

Trastuzumab

8mg/kg

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

National OncoVenture

OTHER

lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT01746771 - A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter